1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Novel therapies in urothelial carcinoma: A biomarker-driven approach
    Journal Article

    Iyer, G.; Rosenberg, J. E.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • First-line nivolumab + ipilimumab in Asian patients with advanced NSCLC and high TMB (≥ 10 mut/Mb): Results from CheckMate 227
    Meeting Abstract

    Park, K.; Lee, J.; Sakai, H.; Lee, K.; Ohe, Y.; Kim, S.; Fukuhara, T.; Kang, J.; Yu, C.; Daga, H.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Tepotinib in non-small cell lung cancer with MET exon 14-skipping mutations or MET amplification: A phase 2 trial in progress
    Meeting Abstract

    Paik, P.; Sakai, H.; Bruns, R.; Scheele, J.; Straub, J.; Felip, E.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK-228
    Meeting Abstract

    Paik, P.; Ahn, L.; Ginsberg, M.; McFarland, D.; Doyle, L.; Rudin, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • SLFN11 expression and efficacy of PARP inhibitor therapy in extensive stage small cell lung cancer: ECOG-ACRIN 2511 study
    Meeting Abstract

    Owonikoko, T.; Dahlberg, S.; Sica, G.; Poirier, J.; Byers, L.; Rudin, C.; Wistuba, I.; Ramalingam, S.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Preliminary clinical activity of repotrectinib (TPX-0005) in advanced ROS1 fusion-positive non-small cell lung cancer
    Meeting Abstract

    Ou, S.; Cho, B. C.; Kim, D.; Drilon, A.; Lee, J.; Lin, J.; Zhu, V.; Ahn, M.; Camidge, D. R.; Shanna Stopatschinskaja, S.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
    Meeting Abstract

    Jänne, P.; Yu, H.; Johnson, M.; Steuer, C.; Vigliotti, M.; Shipitofsky, N.; Guevara, F. M.; Chen, S.; Yu, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
    Meeting Abstract

    Jänne, P.; Yu, H.; Shipitofsky, N.; Vigliotti, M.; Goldberg, T.; Li, J.; Mcgill, J.; Zhang, H.; Yu, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (Alliance A151216)
    Meeting Abstract

    Oxnard, G.; Mandrekar, S.; Hillman, S.; Tan, A.; Govindan, R.; Wigle, D.; Malik, S.; Watt, C.; Gerber, D.; Chaft, J.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Evaluation of PD-L1-stained tumor cells via the 22C3 and SP-142 antibodies in cohort of patients treated on KEYNOTE-001
    Meeting Abstract

    Lisberg, A.; Hu-Lieskovan, S.; Grogan, T.; Carroll, J.; Shintaku, P.; Han, M.; Slamon, D.; Dubinett, S.; Goldman, J.; Elashoff, D.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save